Quantcast

Latest Dopamine agonist Stories

2014-07-31 16:29:24

AZ-002 Phase 2a Study in Patients with Epilepsy Planned for Second Half of 2014 MOUNTAIN VIEW, Calif., July 31, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato(®) alprazolam), which is being developed for the management of patients with acute repetitive seizures. Additionally, Alexza has...

2010-03-31 07:00:00

NASHVILLE, Tenn. and GLEN ROCK, N.J., March 31 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year. According to the new Formulary Forum report entitled Formulary Advantages in Parkinson's Disease: Which...

2009-06-09 08:00:00

Overall Market Will Increase by a Modest $300 Million From 2008 to 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson's disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a result, sales of...

2009-04-29 11:41:00

Data indicated comparable efficacy and safety for extended release and immediate release formulations of pramipexole SEATTLE, April 29 /PRNewswire/ -- New findings from two double-blind studies investigating the efficacy, safety and tolerability of pramipexole dihydrochloride tablets in an extended release, once-daily formulation, for the treatment of Parkinson's disease (PD), are being presented today at the American Academy of Neurology (AAN) 61st Annual Meeting in Seattle. The first...

2006-02-02 13:23:34

By David Douglas NEW YORK (Reuters Health) - A large study confirms that restless legs syndrome (RLS) markedly reduces quality of life and interferes with sleep and that the drug Requip provides significant improvement in symptoms of RLS. "Sleep is important for its restorative properties and treatment of RLS with Requip improves symptoms, sleep disturbance and quality of life in most RLS patients," Dr. Richard Bogan told Reuters Health. Requip, also known as ropinirole, was...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'